高剂量口服维生素D治疗化疗和放疗相关皮肤毒性反应
这项多中心回顾性病例系列纳入33例化疗所致毒性红斑或急性放射性皮炎患者,接受100 000 IU口服维生素D后,87%患者在10天内报告症状缓解,红斑评分从基线4.36降至第10天2.21,未观察到治疗相关不良事件,73%患者未中断抗癌治疗。
要点
- 高剂量口服维生素D可能快速缓解化疗和放疗相关皮肤毒性症状。
- 初步数据显示未出现有意义的血钙变化及治疗相关不良事件。
- 多数患者得以继续抗癌治疗而未中断。
核心结论
- 在这项病例系列中,高剂量口服维生素D与化疗和放疗所致皮肤毒性的症状和客观改善相关,且未报告治疗相关不良事件。
主要发现
- 33例患者中28例(85%)为毒性红斑,5例(15%)为急性放射性皮炎;平均年龄60.9岁(SD 14.6),19例(58%)为女性。
- 30例患者中26例(87%)在治疗10天内报告主观症状缓解;总体中位改善时间为5天(范围1-28天),住院亚组为3天(范围1-16天)。
- 平均红斑Likert评分从基线4.36(SD 0.60)降至第10天2.21(SD 1.36)。
- 中性粒细胞性小汗腺炎和Stevens-Johnson综合征/中毒性表皮坏死松解症样亚型患者反应最快。
- 未观察到血清钙水平有意义的改变,33例中24例(73%)未中断抗癌治疗;研究期间未报告治疗相关不良事件。
关键数值与推荐
- 高剂量口服维生素D剂量为100 000国际单位,给予1或2次口服胆钙化醇或麦角钙化醇。
- 主要结局为患者报告症状缓解时间和临床医生评估的红斑客观改善时间(采用5点Likert量表)。
临床怎么用
- 对于化疗所致毒性红斑或急性放射性皮炎患者,高剂量口服维生素D可能作为支持治疗选择,有助于快速缓解症状并维持抗癌治疗连续性。
- 治疗期间需关注血清钙水平,尽管本研究中未观察到有意义的改变。
局限性
- 回顾性病例系列设计,样本量小(33例),缺乏对照组,结论需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Severe cutaneous toxic effects from chemotherapy and radiation often require treatment interruptions. High-dose oral vitamin D (hdVD) has shown potential as a rapid immunomodulator in experimental models and small human studies, but robust clinical data in oncology populations remain limited. OBJECTIVE: To evaluate the clinical response, safety profile, and time to improvement for hdVD in patients with toxic erythema of chemotherapy (TEC) and acute radiation dermatitis (ARD). DESIGN, SETTING, AND PARTICIPANTS: This retrospective multicenter case series included 33 patients treated across 3 academic medical centers between December 2021 and January 2024. Eligible participants were those receiving hdVD (100 000 international units) for TEC or ARD with at least 10 days of follow-up. EXPOSURES: One or 2 oral doses of 100 000 international units of cholecalciferol or ergocalciferol. MAIN OUTCOMES AND MEASURES: The primary outcomes were time to patient-reported symptomatic relief and clinician-assessed objective improvement in erythema (using a 5-point Likert scale). Secondary outcomes included changes in serum calcium and the ability to continue anticancer therapy. RESULTS: Among 33 patients (mean [SD] age, 60.9 [14.6] years; 19 [58%] female), 28 (85%) had TEC and 5 (15%) had ARD. Subjective symptom relief was reported by 26 of 30 patients (87%) within 10 days of treatment. The median (range) time to improvement was 5 (1-28) days overall and 3 (1-16) days for the inpatient subgroup. The mean (SD) Likert erythema score decreased from 4.36 (0.60) at baseline to 2.21 (1.36) by day 10. Patients with neutrophilic eccrine hidradenitis and Stevens-Johnson syndrome/toxic epidermal necrolysis-like subtypes showed the most rapid responses. No meaningful changes in serum calcium levels were observed, and 24 of the 33 patients (73%) continued anticancer therapy without interruption. No treatment-related adverse events were reported during the study. CONCLUSIONS AND RELEVANCE: In this case series, hdVD was associated with rapid symptomatic and objective improvement in chemotherapy- and radiation-induced toxic effects of the skin without treatment-related adverse events. These findings support further study of hdVD as a supportive care approach in oncodermatology.
引用
- Patil MK, Sakunchotpanit G, Toulmin SA, et al. High-Dose Oral Vitamin D for Toxic Effects of the Skin Associated With Chemotherapy and Radiation. JAMA Dermatol. 2026. PMID: 42455544. doi:10.1001/jamadermatol.2026.2267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。